Global Oligonucleotide Therapeutics Market Size, Share, and COVID-19 Impact Analysis, Russia-Ukraine War Impact, Tariff Analysis, By Treatment Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, and RNAi), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, and Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Oligonucleotide Therapeutics Market Size Insights Forecasts to 2035

• The Global Oligonucleotide Therapeutics Market Size Was Estimated at USD 26.8 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 13.65% from 2025 to 2035
• The Worldwide Oligonucleotide Therapeutics Market Size is Expected to Reach USD 109.5 Billion by 2035
• Asia Pacific is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Oligonucleotide Therapeutics Market Size was worth around USD 26.8 Billion in 2024 and is predicted to Grow to around USD 109.5 Billion by 2035 with a compound annual growth rate (CAGR) of 13.65 % from 2025 to 2035. There is an increasing development of oligonucleotide therapeutics for treating chronic diseases, different from conventional medicine by targeting specific genes. It is anticipated that the increasing demand for gene-based therapies, advancements in molecular diagnostics, and research in genomics & personalized medicine support market growth.

Global Oligonucleotide Therapeutics Market Forecast and Revenue Outlook

• 2024 Market Size: USD 26.8 Billion
• 2035 Projected Market Size: USD 109.5 Billion
• CAGR (2025-2035): 13.65%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Market Overview

The oligonucleotide therapeutics market is the industry encompassing the development, manufacturing, and commercialization of drugs based on short, synthetic strands of DNA or RNA. Oligonucleotide therapeutics work by binding via Watson-Crick base pairing to enhance or repress the expression of the target RNA gene, thereby aiding in treating or managing a wide range of diseases. The single- or double-stranded small synthetic nucleic acid polymers in oligonucleotides are used for modulating gene expression, by targeting pre-mRNA, mRNA, or non-coding RNA to induce degradation, modulate splicing events, or interfere with protein translation. Chemically modified artificial nucleic acids are used for the development of oligonucleotide therapeutics.

The global market share is anticipated to be supported by expanding R&D efforts by major industry participants, including Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Sarepta Therapeutics, emphasizing advancements in novel oligonucleotide therapies for various conditions. There are opportunities in the developing market due to the integration with gene editing tools like CRISPR for enhancing the precision of therapies. Furthermore, strategic investment by key companies like Cohance Lifesciences Ltd. is required to deliver speed, quality, and flexibility in next-generation therapeutics. For instance, in January 2025, Sanofi inks $400M biobucks deal to test the mettle of Alloy’s antisense platform, to enable the development of a central nervous system drug.

Key Market Insights

• North America is expected to account for the largest share in the Oligonucleotide Therapeutics Market during the forecast period.
• In terms of type, the antisense segment is projected to lead the oligonucleotide therapeutics market with a major share throughout the forecast period
• In terms of application, the oncology segment is leading the oligonucleotide therapeutics market during the forecast period.

Oligonucleotide Therapeutics Market Trends

• Increasing demand for personalized medicine and developing targeted therapies as per the individual patient’s traits
• Use of APIs in gene therapy, demonstrating encouraging outcomes in addressing genetic disorders
• Advancements in oligonucleotide synthesis technology
• Regulatory support for advancing and commercializing oligonucleotide therapeutics

Report Coverage

This research report categorizes the oligonucleotide therapeutics market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the oligonucleotide therapeutics Market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the oligonucleotide therapeutics market.

Driving factors

An increasing demand for gene therapies for genetic disorders, rare diseases, and specific types of cancer, along with investments in gene therapy research, is contributing to the escalation of the oligonucleotide therapeutics market. The widespread use of oligonucleotides in biomedical research and therapeutics is driving the market expansion as it plays a crucial role in gene expression, disease treatment, and molecular detection. Additionally, increasing investment by the government and private sector in the field of genomics and molecular biology research is promoting the market for oligonucleotide therapeutics.

Restraining Factor

One of the main factors restraining the oligonucleotide therapeutics market is the complexity and cost related to oligonucleotide drug development and production. Further, regulatory complexities requiring specialized evaluation processes are challenging the market

Market Segmentation 

The global oligonucleotide therapeutics market is divided into treatment type and application.

Global Oligonucleotide Therapeutics Market, By Treatment Type:

• The antisense segment held a major market share in 2024 and is projected to grow at a substantial CAGR during the forecast period.   

Based on treatment type, the global oligonucleotide therapeutics market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/immunostimulatory, and RNAi. Among these, the antisense segment held a major market share in 2024 and is projected to grow at a substantial CAGR during the forecast period. This is attributed to its widespread application in oncology and genetic disorders. Antisense oligonucleotide therapy involves targeting mRNA and modulating protein expression.

The RNAi segment is anticipated to grow at the fastest CAGR during the forecast period, due to its increasing adoption for advancements in delivery systems like nanoparticle-based technologies. The use of RNA-based therapies in various stages of clinical trials for diseases like viral infections, metabolic disorders, and neurological conditions is driving the market.

Global Oligonucleotide Therapeutics Market, By Application:

• The oncology segment accounted for the leading market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on application, the global oligonucleotide therapeutics market is segmented into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and others. Among these, the oncology segment accounted for the leading market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. An increasing demand for targeted therapies in oncology, with the growing prevalence of cancer, is driving the market demand. Oligonucleotides have a crucial role in cancer therapeutic approaches with reduced toxicity as compared to conventional chemotherapeutics.

The neurodegenerative disorders segment is anticipated to grow at the fastest CAGR during the forecast period. Antisense oligonucleotides and small interfering RNAs are offering a promising approach for treating neurodegenerative disorder by addressing the genetic root causes of condition. The growing prevalence of conditions like Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders is anticipated to propel the market.

Regional Segment Analysis of the Global Oligonucleotide Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America Oligonucleotide Therapeutics Market Trends

North America is expected to hold the largest share of the global oligonucleotide therapeutics market over the forecast period.

The North American region's supremacy includes the presence of a well-established biotechnology infrastructure and a strong pipeline of innovative therapies. The expanding application of antisense oligonucleotides and small interfering RNA for treating rare and inherited genetic disorders is propelling the market demand.

U.S. Oligonucleotide Therapeutics Market Trends

With the increasing need for molecular diagnostics, the potential of oligonucleotide therapeutics for incurable indications like cardiovascular diseases, retinal disorders, and cancer is driving the market demand. Further, personalized medicine and research on genetic disorders are supporting the oligonucleotide therapeutics market.

Asia Pacific Oligonucleotide Therapeutics Market Trends

Asia Pacific is expected to grow at the fastest CAGR in the oligonucleotide therapeutics market during the forecast period. This is attributed to the robust biotechnology investments, along with an increasing prevalence of chronic and genetic diseases. Further, government investment in the biotechnology sector and advancements in gene editing technologies aid in propelling market growth.

China Oligonucleotide Therapeutics Market Trends

Increasing development of oligonucleotide drugs, along with increasing innovation and technological breakthroughs, are supporting the oligonucleotide therapeutics market. Additionally, an increasing number of patients population suffering from genetic and chronic disorders is contributing to driving market demand.

Europe Oligonucleotide Therapeutics Market Trends

Europe is anticipated to grow at a rapid CAGR, followed by the Asia Pacific region in the oligonucleotide therapeutics market, owing to the innovation in RNA-based therapeutics, especially in oncology and neurodegenerative disorders. Further, the presence of a strong pharmaceutical landscape in countries like Germany is contributing to propel the regional market for oligonucleotide therapeutics.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global oligonucleotide therapeutics market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Worldwide Top Key Players In The Oligonucleotide Therapeutics Market Include

• BPCI Biotech Holding
• SomaGenics Inc
• Hepion Pharmaceuticals
• Alnylam Pharmaceuticals
• Regulus Therapeutics Inc
• PCI Biotech Holding
• SomaGenics Inc
• Ionis Pharmaceuticals
• Gilead Sciences, Inc
• Santaris
• InteRNA Technologies B.V.
• Mirage
• Biogen
• Merck KGaA
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent development

• In April 2025, Creyon Bio, Inc., announced a global licensing and multi-target research collaboration with Eli Lilly and Company focused on the discovery, development, and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases.
• In February 2025, Biogen Inc. and Stoke Therapeutics, Inc., announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease-modifying medicine in development for the treatment of Dravet syndrome.
• In December 2024, the USFDA has approved lezarsen (TRYNGOLZA), an investigational RNA-targeted medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Oligonucleotide Therapeutics Market based on the following segments:

Global Oligonucleotide Therapeutics Market, By Treatment Type

• Antisense
• Ribozymes
• Aptamers
• miRNA
• CpG/Immunostimulatory
• RNAi

Global Oligonucleotide Therapeutics Market, By Application

• Infectious Diseases
• Oncology
• Neurodegenerative Disorders
• Cardiovascular Diseases
• Kidney Diseases
• Others

Global Oligonucleotide Therapeutics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa